Skip to main content
Top
Published in: EJNMMI Research 1/2017

Open Access 01-12-2017 | Original research

New approaches for the reliable in vitro assessment of binding affinity based on high-resolution real-time data acquisition of radioligand-receptor binding kinetics

Authors: Markus Zeilinger, Florian Pichler, Lukas Nics, Wolfgang Wadsak, Helmut Spreitzer, Marcus Hacker, Markus Mitterhauser

Published in: EJNMMI Research | Issue 1/2017

Login to get access

Abstract

Background

Resolving the kinetic mechanisms of biomolecular interactions have become increasingly important in early-phase drug development. Since traditional in vitro methods belong to dose-dependent assessments, binding kinetics is usually overlooked. The present study aimed at the establishment of two novel experimental approaches for the assessment of binding affinity of both, radiolabelled and non-labelled compounds targeting the A3R, based on high-resolution real-time data acquisition of radioligand-receptor binding kinetics. A novel time-resolved competition assay was developed and applied to determine the Ki of eight different A3R antagonists, using CHO-K1 cells stably expressing the hA3R. In addition, a new kinetic real-time cell-binding approach was established to quantify the rate constants k on and k off, as well as the dedicated K d of the A3R agonist [125I]-AB-MECA. Furthermore, lipophilicity measurements were conducted to control influences due to physicochemical properties of the used compounds.

Results

Two novel real-time cell-binding approaches were successfully developed and established. Both experimental procedures were found to visualize the kinetic binding characteristics with high spatial and temporal resolution, resulting in reliable affinity values, which are in good agreement with values previously reported with traditional methods. Taking into account the lipophilicity of the A3R antagonists, no influences on the experimental performance and the resulting affinity were investigated.

Conclusions

Both kinetic binding approaches comprise tracer administration and subsequent binding to living cells, expressing the dedicated target protein. Therefore, the experiments resemble better the true in vivo physiological conditions and provide important markers of cellular feedback and biological response.
Literature
1.
go back to reference Clark AJ. Mode of action of drugs on cells. London: Edward Arnold & Co; 1933. Clark AJ. Mode of action of drugs on cells. London: Edward Arnold & Co; 1933.
2.
go back to reference Motulsky HJ, Mahan LC. The kinetics of competitive radioligand binding predicted by the law of mass action. Mol Pharmacol. 1984;25:1–9.PubMed Motulsky HJ, Mahan LC. The kinetics of competitive radioligand binding predicted by the law of mass action. Mol Pharmacol. 1984;25:1–9.PubMed
3.
go back to reference Cheng Y, Prusoff WH. Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol. 1973;22:3099–108.CrossRefPubMed Cheng Y, Prusoff WH. Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol. 1973;22:3099–108.CrossRefPubMed
4.
go back to reference Hulme EC, Birdsall NJM. Strategy and tactics in receptor-binding studies. In: Hulme EC, editor. Receptor-ligand interactions—a practical approach. Oxford: IRL Press; 1992. p. 63–176. Hulme EC, Birdsall NJM. Strategy and tactics in receptor-binding studies. In: Hulme EC, editor. Receptor-ligand interactions—a practical approach. Oxford: IRL Press; 1992. p. 63–176.
5.
go back to reference Swinney DC. Biochemical mechanisms of drug action: what does it take for success? Nat Rev Drug Discov. 2004;3:801–8.CrossRefPubMed Swinney DC. Biochemical mechanisms of drug action: what does it take for success? Nat Rev Drug Discov. 2004;3:801–8.CrossRefPubMed
6.
go back to reference Swinney DC. The role of binding kinetics in therapeutically useful drug action. Curr Opin Drug Discov Devel. 2009;12:31–9.PubMed Swinney DC. The role of binding kinetics in therapeutically useful drug action. Curr Opin Drug Discov Devel. 2009;12:31–9.PubMed
8.
go back to reference Copeland RA, Pompliano DL, Meek TD. Drug-target residence time and its implication for lead optimization. Nat Rev Drug Discov. 2006;5:730–9.CrossRefPubMed Copeland RA, Pompliano DL, Meek TD. Drug-target residence time and its implication for lead optimization. Nat Rev Drug Discov. 2006;5:730–9.CrossRefPubMed
9.
go back to reference Zhang R, Monsma F. The importance of drug-target residence time. Curr Opin Drug Discov Devel. 2009;12:488–96.PubMed Zhang R, Monsma F. The importance of drug-target residence time. Curr Opin Drug Discov Devel. 2009;12:488–96.PubMed
10.
go back to reference Ojima M, Inada Y, Shibouta Y, Wada T, Sanada T, Kubo K, et al. Candesartan (CV-11974) dissociates slowly from the angiotensin AT1 receptor. Eur J Pharmacol. 1997;319:137–46.CrossRefPubMed Ojima M, Inada Y, Shibouta Y, Wada T, Sanada T, Kubo K, et al. Candesartan (CV-11974) dissociates slowly from the angiotensin AT1 receptor. Eur J Pharmacol. 1997;319:137–46.CrossRefPubMed
11.
go back to reference Anthes JC, Gilchrest H, Richard C, Eckel S, Hesk D, West Jr RE, et al. Biochemical characterization of desloratadine, a potent antagonist of the human histamine H(1) receptor. Eur J Pharmacol. 2002;449:229–37.CrossRefPubMed Anthes JC, Gilchrest H, Richard C, Eckel S, Hesk D, West Jr RE, et al. Biochemical characterization of desloratadine, a potent antagonist of the human histamine H(1) receptor. Eur J Pharmacol. 2002;449:229–37.CrossRefPubMed
12.
go back to reference Dowling MR, Charlton SJ. Quantifying the association and dissociation rates of unlabelled antagonists at the muscarinic M3 receptor. Br J Pharmacol. 2006;148:927–37.CrossRefPubMedPubMedCentral Dowling MR, Charlton SJ. Quantifying the association and dissociation rates of unlabelled antagonists at the muscarinic M3 receptor. Br J Pharmacol. 2006;148:927–37.CrossRefPubMedPubMedCentral
13.
go back to reference Buch I, Giorgino T, De Fabritiis G. Complete reconstruction of an enzyme-inhibitor binding process by molecular dynamics simulations. Proc Natl Acad Sci U S A. 2011;108:10184–9.CrossRefPubMedPubMedCentral Buch I, Giorgino T, De Fabritiis G. Complete reconstruction of an enzyme-inhibitor binding process by molecular dynamics simulations. Proc Natl Acad Sci U S A. 2011;108:10184–9.CrossRefPubMedPubMedCentral
14.
go back to reference Casarosa P, Kollak I, Kiechle T, Ostermann A, Schnapp A, Kiesling R, et al. Functional and biochemical rationales for the 24-hour-long duration of action of olodaterol. J Pharmacol Exp Ther. 2011;337:600–9.CrossRefPubMed Casarosa P, Kollak I, Kiechle T, Ostermann A, Schnapp A, Kiesling R, et al. Functional and biochemical rationales for the 24-hour-long duration of action of olodaterol. J Pharmacol Exp Ther. 2011;337:600–9.CrossRefPubMed
15.
go back to reference Guo D, Van Dorp EJH, Mulder-Krieger T, Van Veldhoven JPD, Brussee J, IJzerman AP, et al. Dual-point competition association assay: a fast and high-throughput kinetic screening method for assessing ligand-receptor binding kinetics. J Biomol Screen. 2012;18:309–20.CrossRefPubMed Guo D, Van Dorp EJH, Mulder-Krieger T, Van Veldhoven JPD, Brussee J, IJzerman AP, et al. Dual-point competition association assay: a fast and high-throughput kinetic screening method for assessing ligand-receptor binding kinetics. J Biomol Screen. 2012;18:309–20.CrossRefPubMed
16.
go back to reference Emami-Nemini A, Roux T, Leblay M, Bourrier E, Lamarque L, Trinquet E, Lohse MJ. Time-resolved fluorescence ligand binding for G protein-coupled receptors. Nat Protoc. 2013;8:1307–20.CrossRefPubMed Emami-Nemini A, Roux T, Leblay M, Bourrier E, Lamarque L, Trinquet E, Lohse MJ. Time-resolved fluorescence ligand binding for G protein-coupled receptors. Nat Protoc. 2013;8:1307–20.CrossRefPubMed
17.
go back to reference Heise CE, Sullivan SK, Crowe PD. Scintillation proximity assay as a high-throughput method to identify slowly dissociating nonpeptide ligand binding to the GnRH receptor. J Biomol Screen. 2007;12:235–9.CrossRefPubMed Heise CE, Sullivan SK, Crowe PD. Scintillation proximity assay as a high-throughput method to identify slowly dissociating nonpeptide ligand binding to the GnRH receptor. J Biomol Screen. 2007;12:235–9.CrossRefPubMed
18.
go back to reference Packeu A, Wennerberg M, Balendran A, Vauquelin G. Estimation of the dissociation rate of unlabelled ligand–receptor complexes by a ‘two-step’ competition binding approach. Br J Pharmacol. 2010;161:1311–28.CrossRefPubMedPubMedCentral Packeu A, Wennerberg M, Balendran A, Vauquelin G. Estimation of the dissociation rate of unlabelled ligand–receptor complexes by a ‘two-step’ competition binding approach. Br J Pharmacol. 2010;161:1311–28.CrossRefPubMedPubMedCentral
19.
go back to reference Björke H, Andersson K. Measuring the affinity of a radioligand with its receptor using a rotating cell dish with in situ reference area. Appl Radiat Isot. 2006;64:32–7.CrossRefPubMed Björke H, Andersson K. Measuring the affinity of a radioligand with its receptor using a rotating cell dish with in situ reference area. Appl Radiat Isot. 2006;64:32–7.CrossRefPubMed
20.
go back to reference Nilvebrant J, Kuku G, Björkelund H, Nestor M. Selection and in vitro characterization of human CD44v6-binding antibody fragments. Biotechnol Appl Biochem. 2012;59:367–80.CrossRefPubMed Nilvebrant J, Kuku G, Björkelund H, Nestor M. Selection and in vitro characterization of human CD44v6-binding antibody fragments. Biotechnol Appl Biochem. 2012;59:367–80.CrossRefPubMed
21.
go back to reference Xu B, Varasteh Z, Orlova A, Andersson K, Larhammar D, Björkelund H. Detecting ligand interactions with G protein-coupled receptors in real-time on living cells. Biochem Biophys Res Commun. 2013;441:820–4.CrossRefPubMed Xu B, Varasteh Z, Orlova A, Andersson K, Larhammar D, Björkelund H. Detecting ligand interactions with G protein-coupled receptors in real-time on living cells. Biochem Biophys Res Commun. 2013;441:820–4.CrossRefPubMed
22.
go back to reference Barta P, Björkelund H, Andersson K. Circumventing the requirement of binding saturation for receptor quantification using interaction kinetic extrapolation. Nucl Med Commun. 2011;3:1–5. Barta P, Björkelund H, Andersson K. Circumventing the requirement of binding saturation for receptor quantification using interaction kinetic extrapolation. Nucl Med Commun. 2011;3:1–5.
23.
go back to reference Bjorke H, Andersson K. Automated, high-resolution cellular retention and uptake studies in vitro. Appl Radiat Isot. 2006;64:901–5.CrossRefPubMed Bjorke H, Andersson K. Automated, high-resolution cellular retention and uptake studies in vitro. Appl Radiat Isot. 2006;64:901–5.CrossRefPubMed
24.
go back to reference Björkelund H, Gedda L, Malmqvist M, Andersson K. Resolving the EGF-EGFR interaction characteristics through a multiple-temperature, multiple-inhibitor, real-time interaction analysis approach. Mol Clin Oncol. 2013;1:343–52.PubMed Björkelund H, Gedda L, Malmqvist M, Andersson K. Resolving the EGF-EGFR interaction characteristics through a multiple-temperature, multiple-inhibitor, real-time interaction analysis approach. Mol Clin Oncol. 2013;1:343–52.PubMed
25.
go back to reference Spiegelberg D, Stenberg J, Haylock AK, Nestor M. A real-time in vitro assay as a potential predictor of in vivo tumor imaging properties. Nucl Med Biol. 2016;43:12–8.CrossRefPubMed Spiegelberg D, Stenberg J, Haylock AK, Nestor M. A real-time in vitro assay as a potential predictor of in vivo tumor imaging properties. Nucl Med Biol. 2016;43:12–8.CrossRefPubMed
26.
go back to reference Stenberg J, Spiegelberg D, Karlsson H, Nestor M. Choice of labeling and cell line influences interactions between the Fab fragment AbD15179 and its target antigen CD44v6. Nucl Med Biol. 2014;41:140–7.CrossRefPubMed Stenberg J, Spiegelberg D, Karlsson H, Nestor M. Choice of labeling and cell line influences interactions between the Fab fragment AbD15179 and its target antigen CD44v6. Nucl Med Biol. 2014;41:140–7.CrossRefPubMed
27.
go back to reference Fredholm BB, IJzerman AP, Jacobson KA, Klotz KN, Linden J. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev. 2001;53:527–52.PubMed Fredholm BB, IJzerman AP, Jacobson KA, Klotz KN, Linden J. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev. 2001;53:527–52.PubMed
28.
go back to reference Fredholm BB, IJzerman AP, Jacobson KA, Linden J, Müller CE. International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors—an update. Pharmacol Rev. 2011;63:1–34.CrossRefPubMedPubMedCentral Fredholm BB, IJzerman AP, Jacobson KA, Linden J, Müller CE. International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors—an update. Pharmacol Rev. 2011;63:1–34.CrossRefPubMedPubMedCentral
29.
30.
go back to reference von Lubitz D, Simpson K, Lin R. Right thing at a wrong time? Adenosine A3 receptors and cerebroprotection in stroke. Ann N Y Acad Sci. 2001;939:85–96.CrossRef von Lubitz D, Simpson K, Lin R. Right thing at a wrong time? Adenosine A3 receptors and cerebroprotection in stroke. Ann N Y Acad Sci. 2001;939:85–96.CrossRef
32.
go back to reference Olah ME, Gallo-Rodriguez C, Jacobson KA, Stiles GL. 125I-4-aminobenzyl-5′-N-methylcarboxamidoadenosine, a high affinity radioligand for the rat A3 adenosine receptor. Mol Pharmacol. 1994;45:978–82.PubMed Olah ME, Gallo-Rodriguez C, Jacobson KA, Stiles GL. 125I-4-aminobenzyl-5′-N-methylcarboxamidoadenosine, a high affinity radioligand for the rat A3 adenosine receptor. Mol Pharmacol. 1994;45:978–82.PubMed
33.
go back to reference Ji XD, Melman N, Jacobson KA. Interactions of flavonoids and other phytochemicals with adenosine receptors. J Med Chem. 1996;39:781–8.CrossRefPubMed Ji XD, Melman N, Jacobson KA. Interactions of flavonoids and other phytochemicals with adenosine receptors. J Med Chem. 1996;39:781–8.CrossRefPubMed
34.
go back to reference Jiang JL, van Rhee AM, Melman N, Ji XD, Jacobson KA. 6-phenyl-1,4-dihydropyridine derivatives as potent and selective A3 adenosine receptor antagonists. J Med Chem. 1996;39:4667–75.CrossRefPubMed Jiang JL, van Rhee AM, Melman N, Ji XD, Jacobson KA. 6-phenyl-1,4-dihydropyridine derivatives as potent and selective A3 adenosine receptor antagonists. J Med Chem. 1996;39:4667–75.CrossRefPubMed
35.
go back to reference Jacobson KA, Park KS, Jiang JL, Kim YC, Olah ME, Stiles GL, Ji XD. Pharmacological characterization of novel A3 adenosine receptor-selective antagonists. Neuropharmacology. 1997;36:1157–65.CrossRefPubMedPubMedCentral Jacobson KA, Park KS, Jiang JL, Kim YC, Olah ME, Stiles GL, Ji XD. Pharmacological characterization of novel A3 adenosine receptor-selective antagonists. Neuropharmacology. 1997;36:1157–65.CrossRefPubMedPubMedCentral
36.
go back to reference Li AH, Moro S, Melman N, Ji XD, Jacobson KA. Structure-activity relationships and molecular modeling of 3,5-diacyl-2,4-dialkylpyridine derivatives as selective A3 adenosine receptor antagonists. J Med Chem. 1998;41:3186–201.CrossRefPubMedPubMedCentral Li AH, Moro S, Melman N, Ji XD, Jacobson KA. Structure-activity relationships and molecular modeling of 3,5-diacyl-2,4-dialkylpyridine derivatives as selective A3 adenosine receptor antagonists. J Med Chem. 1998;41:3186–201.CrossRefPubMedPubMedCentral
37.
go back to reference Li AH, Moro S, Forsyth N, Melman N, Ji XD, Jacobson KA. Synthesis, CoMFA analysis, and receptor docking of 3,5-diacyl-2,4-dialkylpyridine derivates as selective A3 adenosine receptor antagonists. J Med Chem. 1999;42:706–21.CrossRefPubMed Li AH, Moro S, Forsyth N, Melman N, Ji XD, Jacobson KA. Synthesis, CoMFA analysis, and receptor docking of 3,5-diacyl-2,4-dialkylpyridine derivates as selective A3 adenosine receptor antagonists. J Med Chem. 1999;42:706–21.CrossRefPubMed
38.
go back to reference Shanab K, Wadsak W, Mien LK, Mitterhauser M, Holzer W, Polster V, et al. Synthesis of in vivo metabolites of the new adenosine A3 receptor PET-radiotracer [18F]FE@SUPPY. Heterocycles. 2008;75:339–56.CrossRef Shanab K, Wadsak W, Mien LK, Mitterhauser M, Holzer W, Polster V, et al. Synthesis of in vivo metabolites of the new adenosine A3 receptor PET-radiotracer [18F]FE@SUPPY. Heterocycles. 2008;75:339–56.CrossRef
39.
go back to reference Haeusler D, Mitterhauser M, Mien LK, Shanab K, Lanzenberger R, Schirmer E, et al. Radiosynthesis of a novel potential adenosine A3 receptor ligand, 5-ethyl 2,4-diethyl-3-((2-[18F]fluoroethyl(sulfanylcarbonyl)-6-phenylpyridine-5-carboxylate ([18F]FE@SUPPY:2). Radiochem Acta. 2009;97:753–8.CrossRef Haeusler D, Mitterhauser M, Mien LK, Shanab K, Lanzenberger R, Schirmer E, et al. Radiosynthesis of a novel potential adenosine A3 receptor ligand, 5-ethyl 2,4-diethyl-3-((2-[18F]fluoroethyl(sulfanylcarbonyl)-6-phenylpyridine-5-carboxylate ([18F]FE@SUPPY:2). Radiochem Acta. 2009;97:753–8.CrossRef
40.
go back to reference Klotz KN, Hessling J, Hegler J, Owman C, Kull B, Fredholm BB, Lohse MJ. Comparative pharmacology of human adenosine receptor subtypes—characterization of stably transfected receptors in CHO cells. Naunyn Schmiedebergs Arch Pharmacol. 1998;357:1–9.CrossRefPubMed Klotz KN, Hessling J, Hegler J, Owman C, Kull B, Fredholm BB, Lohse MJ. Comparative pharmacology of human adenosine receptor subtypes—characterization of stably transfected receptors in CHO cells. Naunyn Schmiedebergs Arch Pharmacol. 1998;357:1–9.CrossRefPubMed
41.
go back to reference Donovan SF, Pescatore MC. Method for measuring the logarithm of the octanol-water partition coefficient by using short octadecyl-poly(vinyl alcohol) high-performance liquid chromatography columns. J Chromatogr A. 2002;952:47–61.CrossRefPubMed Donovan SF, Pescatore MC. Method for measuring the logarithm of the octanol-water partition coefficient by using short octadecyl-poly(vinyl alcohol) high-performance liquid chromatography columns. J Chromatogr A. 2002;952:47–61.CrossRefPubMed
Metadata
Title
New approaches for the reliable in vitro assessment of binding affinity based on high-resolution real-time data acquisition of radioligand-receptor binding kinetics
Authors
Markus Zeilinger
Florian Pichler
Lukas Nics
Wolfgang Wadsak
Helmut Spreitzer
Marcus Hacker
Markus Mitterhauser
Publication date
01-12-2017
Publisher
Springer Berlin Heidelberg
Published in
EJNMMI Research / Issue 1/2017
Electronic ISSN: 2191-219X
DOI
https://doi.org/10.1186/s13550-016-0249-9

Other articles of this Issue 1/2017

EJNMMI Research 1/2017 Go to the issue